Medical inquiries

Connect with my medical science liaison

Chat live

Available Monday - Friday 9AM - 4:30PM ET

Call me now

Available Monday - Friday 9AM - 7:30PM ET

Email your inquiry

Call 1-800-526-7736

Available Monday - Friday 9AM - 8PM ET

Live video

Available Monday - Friday 9AM - 4:30PM ET

This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.

RYBREVANT® (amivantamab-vmjw)

Medical Information

+ Save link

RYBREVANT - Latex Content

Last Updated: 06/10/2024

SUMMARY

RYBREVANT (amivantamab-vmjw) injection is supplied as a sterile, preservative-free, colorless to pale yellow solution for intravenous infusion. Each single dose vial contains 350 mg/7 mL (50 mg/mL) RYBREVANT. Each vial is individually packed in a single carton (NDC 57894-501-01).¹
The materials (ie, the immediate container and excipients) do not contain latex as an ingredient; however, it cannot be guaranteed that the materials do not come in contact with latex during the manufacturing or packaging process (eg, latex gloves).²

LITERATURE SEARCH

A literature search of MEDLINE^®, Embase^®, BIOSIS Previews^®, and Derwent Drug File (and/or other resources, including internal/external databases) was conducted on 07 June 2024.

References

Show

1	RYBREVANT (amivantamab-vmjw) [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.;https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/RYBREVANT-pi.pdf.
2	Data on File. Technical Document Patient Safety and Compliance Information. Janssen Research & Development, LLC. TV-TEC-182797; 2022.